The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InLifecore Biomedical (LFCR) announced it has signed a manufacturing services agreement with a leading medical aesthetics company for an established, market-approved product. Under the terms of the deal, Lifecore will serve as the contract development and manufacturing organization (CDMO) for the aesthetic product. This marks the company's third commercial site transfer agreement win within the last five months, highlighting strong business momentum in its specialized niche. The program is anticipated to start generating commercial revenue within the next 24 months. Management expects this partnership to contribute significantly to the company's revenue compound annual growth rate (CAGR) through 2029. The agreement aligns with Lifecore's strategic focus on expanding its injectable manufacturing capabilities and strengthening its long-term CDMO pipeline.